A federal grand jury in the District of Columbia returned a five-count indictment on May 7, 2026, charging 11 men for their alleged roles in a transnational drug trafficking organization that sourced methamphetamine from California and gamma-butyrolactone (GBL) from South Korea and distributed both substances along the Northeast Corridor from New York City to Washington, D.C. [1] U.S. Attorney Jeanine Ferris Pirro announced the charges, which carry mandatory minimum sentences of 10 years and a maximum of life in federal prison [1].
The indictment names Colton Keet Huthsing as the alleged ringleader and charges him with coordinating distribution across multiple states and laundering drug proceeds through sham beauty companies [1]. GBL, a controlled substance often used as a precursor to GHB, was imported directly from South Korea, reflecting the organization's capacity to source product internationally rather than relying solely on domestic supply chains [1]. The multi-state footprint, the use of foreign supply lines, and the front-company laundering structure place this case in a category of prosecutions that federal authorities have increasingly prioritized as drug trafficking organizations adopt corporate concealment techniques.
The FBI, the Drug Enforcement Administration, and the Homeland Security Investigations Task Force jointly investigated the case [1]. The indictment was returned in the U.S. District Court for the District of Columbia. No trial date has been publicly announced, and it remains unclear from available sources how many of the 11 defendants are in custody. Under the Controlled Substances Act, the charged conduct, if proved, supports the mandatory minimum sentencing range that Pirro announced.
The prosecution reflects a coordinated federal effort to dismantle distribution networks operating along the densely populated Northeast Corridor, where demand for both methamphetamine and club-adjacent substances has drawn sustained law enforcement attention. The next procedural steps will include arraignments, probable detention hearings for defendants in custody, and the government's disclosure obligations under the Jencks Act and Brady doctrine, all of which will shape the litigation timeline. Defense challenges to the money laundering counts, particularly the government's theory that beauty companies served as shell vehicles, are likely to emerge as a central contested issue in pretrial motions.